A Study of LY3502970 in Participants With Type 2 Diabetes

Lilly

Status and phase

Completed

Phase 1

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: LY3502970

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04426474

2020-000125-86 (EudraCT Number)

17681

J2A-MC-GZGC (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.

Enrollment

68 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Have type 2 diabetes mellitus (T2DM) for at least 6 months
Have a glycated hemoglobin (HbA1c) value at screening of greater than or equal to (≥)7.0 percent (%) and less than or equal to (≤)10.5% and are treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening
Have a body weight of ≥45 kilograms (kg) and have a body mass index of 18.5 to 45 kilograms per square meter (kg/m²), inclusive
Have had a stable body weight for the 3 months prior to screening (less than [<]5% body weight change)
Males and females (not considered woman of childbearing potential)

Exclusion criteria

Have type 1 diabetes mellitus, latent autoimmune diabetes in adults or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening
Have had any of the following within the past 6 months prior to screening: myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack, cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure
Show evidence of hepatitis B, and/or positive hepatitis B surface antigen
Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
Any glucose-lowering medications other than metformin within 3 months prior to screening